# US 2026/0077025 A1 · Sialylated glycoprotein composition and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0077025 A1
- Document ID: US20260077025A1
- Status: Published application
- Kind: A1
- Application number: 19/272,719
- Filed: 2025-07-17
- Published: 2026-03-19
- Earliest claimed: 2014-03-05
- Applicants: Ultragenyx Pharmaceutical Inc.
- Inventors: Steven JUNGLES; Gabrielle MORRIS; Jeff GRUBB; Michael VELLARD; Emil D. KAKKIS
- Web page: https://patentgrep.com/patent/US20260077025A1

## CPC

- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 9/24: acting on glycosyl compounds (3.2)
- C12N 9/2402: {hydrolysing O- and S- glycosyl compounds (3.2.1)}
- C12N 9/2468: {acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)}
- C12Y 302/01031: Beta-glucuronidase (3.2.1.31)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present application relates to sialylated glycoprotein compositions and methods of their use in treating various conditions and disorders.

## Claims

### Claim at position 1

1-27. (canceled)

### Claim 28

A composition comprising a recombinant glycoprotein, wherein the recombinant glycoprotein is human β-glucuronidase and has a sialylation content of at least 0.7 mol/mol of the recombinant glycoprotein.

### Claim 29 (depends on 28)

The composition of claim 28, wherein the recombinant glycoprotein has a high level of mannose-6-phosphate (M6P) moieties.

### Claim 30 (depends on 28)

The composition of claim 28, wherein the recombinant glycoprotein has a sialylation content of at least 1 mol/mol and a high level of M6P moieties of at least 10 mol % of the total glycan of the recombinant glycoprotein.

### Claim 31 (depends on 28)

The composition of claim 28, wherein the recombinant glycoprotein has a high level of M6P moieties and a M6P dependent half-maximum concentration of no more than 3 nM of the recombinant glycoprotein into human fibroblast cells.

### Claim 32

A preparation of a population of a recombinant glycoprotein, wherein the recombinant protein is human β-glucuronidase and wherein at least 10% percentage of the population of the recombinant glycoprotein is sialylated.

### Claim 33 (depends on 32)

The preparation of claim 32, wherein the recombinant protein has a sialylation content of at least 0.7 mol/mol of the recombinant protein.

### Claim 34 (depends on 32)

The preparation of claim 32, wherein the recombinant protein has a high level of M6P moieties.

### Claim 35 (depends on 32)

The preparation of claim 32, wherein the recombinant protein has a sialylation content of at least 1 mol/mol and a high level of M6P moieties of at least 10 mol % of the total glycan of the recombinant glycoprotein.

### Claim 36 (depends on 32)

The preparation of claim 32, wherein the recombinant glycoprotein has a high level of M6P moieties and an half-maximum uptake concentration of not more than 3 nM of the recombinant glycoprotein into human fibroblast cells.

### Claim 37 (depends on 28)

A method of making the composition of claim 28 comprising expressing the recombinant glycoprotein in a cell culture with a serum or protein free media.

### Claim 38 (depends on 32)

A method of making the preparation of claim 32 comprising expressing the recombinant glycoprotein in a cell culture with a serum or protein free media.

### Claim 39 (depends on 28)

A method of treating multi-system lysosomal storage disorder comprising administering to an individual in need of such treatment an therapeutically effective amount of the composition of claim 28.

### Claim 40

A method for treating a condition or disorder in a subject, comprising administering to the subject a regimen comprising a recombinant glycoprotein that has a sialylation content of at least 0.7 mol/mol of the recombinant glycoprotein, wherein the administration provides a statistically significant therapeutic effect for the treatment of the condition or disorder.
